Aktionsplan Greenwich LifeSciences, Inc.
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.| IPO date | 2020-09-25 |
|---|---|
| ISIN | US3968791083 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://greenwichlifesciences.com |
| Цена ао | 11.78 |
| Preisänderung pro Tag: | +1.87% (11.78) |
|---|---|
| Preisänderung pro Woche: | -0.8264% (12.1) |
| Preisänderung pro Monat: | +0.2506% (11.97) |
| Preisänderung über 3 Monate: | -11.18% (13.51) |
| Preisänderung über sechs Monate: | -16.9% (14.44) |
| Preisänderung pro Jahr: | -31.43% (17.5) |
| Preisänderung über 3 Jahre: | -43.05% (21.07) |
| Preisänderung seit Jahresbeginn: | -3.15% (12.39) |
|
|
Unterschätzung
|
Effizienz
|
|||||||||||||||||||||||||||||||||||||
Dividenden
|
Pflicht
|
Wachstumsimpuls
|
|||||||||||||||||||||||||||||||||||||
| Institutionen | Volumen | Aktie, % |
|---|---|---|
| Vanguard Group Inc | 221682 | 1.73 |
| Blackrock Inc. | 57148 | 0.44 |
| Ameriprise Financial, Inc. | 53647 | 0.42 |
| Geode Capital Management, LLC | 46816 | 0.36 |
| Renaissance Technologies, LLC | 36600 | 0.28 |
| Northern Trust Corporation | 20983 | 0.16 |
| 683 Capital Management LLC | 19604 | 0.15 |
| Qube Research & Technologies Ltd | 14714 | 0.11 |
| JANE STREET GROUP, LLC | 14005 | 0.11 |
| State Street Corporation | 13002 | 0.1 |
| ETF | Aktie, % | Rentabilität für das Jahr, % | Dividenden, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02306 | 17.09 | 1.54048 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 23.05 | 0.60264 |
iShares Russell 2000 Growth ETF
|
0.00627 | 38.04 | 0.6026 |
ProShares UltraPro Russell2000
|
0.00192 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.0005 | 5.92 | 1.47892 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Aufsicht | Berufsbezeichnung | Zahlung | Geburtsjahr |
|---|---|---|---|
| Mr. Snehal S. Patel | CEO, CFO & Director | 1.09M | 1964 (61 Jahr) |
| Mr. Eric Rothe | Founder & Independent Director | 65.64k | 1976 (49 Jahre) |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | N/A | 1951 (74 Jahr) |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | N/A | 1966 (59 Jahre) |
| Dr. Christine T. Fischette Ph.D. | VP of Business Development | N/A | 1951 (74 Jahr) |
Adresse: United States, Stafford. TX, Building 14 - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://greenwichlifesciences.com
Webseite: https://greenwichlifesciences.com
